Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+44.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+44.4%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
3x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$16.54M+32.6%
2024$12.47M+97.3%
2023$6.32M+15.0%
2022$5.50M-12.6%
2021$6.29M-